This trial is testing the safety and effectiveness of two long-acting HIV medications given either together or alone.
2 Primary · 4 Secondary · Reporting Duration: Up to 72 weeks
135 Total Participants · 5 Treatment Groups
Primary Treatment: RPV LA · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 55 · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|PRA Health Sciences||100.0%|